This hypothesis is based on previous work that highlights PAR1 as the orchestrating receptor of macrophage–tumor cell interactions in PDAC and on the fact that MMP9 has recently been identified as a novel PAR1 agonist [18]. Here, MMP9 is linked to neoplasm.